Directori de persones
Nuria Eritja Sanchez

Nuria Eritja Sanchez

Grau: Doctor/a

973 70 29 37
neritja(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/M-1347-2015

Grups

Publicacions

  • Yeramian, Andree; Santacana, Maria; Sorolla, Anabel; Llobet, David; Encinas, Mario; Velasco, Ana; Bahi, Nuria; Eritja, Nuria; Domingo, Monica; Oliva, Esther; Dolcet, Xavier; Matias-Guiu, Xavier

    Nuclear factor-?B2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1a independent manner.

    LABORATORY INVESTIGATION 91 859-871. .

    [doi:10.1038/labinvest.2011.58]

  • Llobet, David; Eritja, Nuria; Domingo, Monica; Bergada, Laura; Mirantes, Cristina; Santacana, Maria; Pallares, Judit; Macia, Anna; Yeramian, Andree; Encinas, Mario; Moreno-Bueno, Gema; Palacios, Jose; Lewis, Robert E.; Matias-Guiu, Xavier; Dolcet, Xavi

    KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.

    AMERICAN JOURNAL OF PATHOLOGY 178 1529-1543. .

    [doi:10.1016/j.ajpath.2010.12.041]

  • Eritja, Nuria; Llobet, David; Domingo, Monica; Santacana, Maria; Yeramian, Andree; Matias-Guiu, Xavier; Dolcet, Xavi

    A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.

    AMERICAN JOURNAL OF PATHOLOGY 176 2722-2731. .

    [doi:10.2353/ajpath.2010.090974]

  • Llobet, D.; Eritja, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Domingo, M.; Santacana, M.; Gonzalez-Tallada, F. J.; Matias-Guiu, X.; Dolcet, X.

    The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.

    EUROPEAN JOURNAL OF CANCER 46 836-850. .

    [doi:10.1016/j.ejca.2009.12.025]

  • Llobet, D.; Pallares, J.; Yeramian, A.; Santacana, M.; Eritja, N.; Velasco, A.; Dolcet, X.; Matias-Guiu, X.

    Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.

    JOURNAL OF CLINICAL PATHOLOGY 62 777-785. .

    [doi:10.1136/jcp.2008.056101]

  • Pallares, Judit; Santacana, Maria; Puente, Soraya; Lopez, Susana; Yeramian, Andree; Eritja, Nuria; Sorolla, Anabel; Llobet, David; Dolcet, Xavier; Matias-Guiu, Xavier

    A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.

    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY 31 217-226. .

  • Pallares, Judit; Llobet, David; Santacana, Maria; Eritja, Nuria; Velasco, Ana; Cuevas, Dolors; Lopez, Susana; Palomar-Asenjo, Victor; Yeramian, Andree; Dolcet, Xavier; Matias-Guiu, Xavier

    CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.

    AMERICAN JOURNAL OF PATHOLOGY 174 287-296. .

    [doi:10.2353/ajpath.2009.080552]

  • Gallel, Pitar; Pallares, Judit; Dolcet, Xavier; Llobet, David; Eritja, Nuria; Santacana, Maria; Yeramian, Andre; Palomar-Asenjo, Victor; Lagarda, Helena; Mauricio, Didac; Encinas, Mario; Matias-Guiu, Xavier

    Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.

    HUMAN PATHOLOGY 39 994-1001. .

    [doi:10.1016/j.humpath.2007.11.015]

  • Velasco, Ana; Pallares, Judit; Santacana, Maria; Yeramian, Andre; Dolcet, Xavier; Eritja, Nuria; Puente, Soraya; Sorolla, Anabel; Llecha, Nuria; Matias-Guiu, Xavier

    Loss of heterozygosity in endometrial carcinoma

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY 27 305-317. .

    [doi:10.1097/PGP.0b013e31815dafla]

  • Velasco A; Pallares J; Santacana M; Yeramian A; Dolcet X; Eritja N; Puente S; Sorolla A; Llecha N; Matias-Guiu X

    Loss of heterozygosity in endometrial carcinoma.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY 27 305-317. .

    [doi:10.1097/PGP.0b013e31815daf1a]

  • Pallares, Judit; Velasco, Ana; Eritja, Nuria; Santacana, Maria; Dolcet, Xavier; Cuatrecasas, Miriam; Palomar-Asenjo, Victor; Catasus, Lluis; Prat, Jaime; Matias-Guiu, Xavier

    Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.

    Modern Pathology 21 691-699. .

    [doi:10.1038/modpathol.2008.38]

  • Llobet, D.; Eritja, N.; Encinas, M.; Llecha, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Gonzalez-Tallada, F. J.; Matias-Guiu, X.; Dolcet, X.

    CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.

    ONCOGENE 27 2513-2524. .

    [doi:10.1038/sj.onc.1210924]

Projectes

  • Implicación de ARID1A en la remodelación del microambiente tumoral y la reprogramación metabólica en el cáncer endometrial
  • Papel de ARID1A en la carcinogénesis endometrial dependiente de contexto. Análisis de los mecanismos moleculares y posibles implicaciones terapéuticas
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • Contrato Miguel Servet - RRHH
  • Contrato Miguel Servet - Proyecto
  • LYOTEK
  • "Determinación del perfil metabólico del carcinoma endometrioide de endometrio grado 3 para discriminar los subtipos tumorales establecidos por clasificación del TCGA (The Cancer Genome Atlas Research Network)"
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
  • DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
  • Genomic approach for individualizing endometrial cancer diagnosis, prognosis and treatment